AR109706A1 - INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g - Google Patents

INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g

Info

Publication number
AR109706A1
AR109706A1 ARP170102631A ARP170102631A AR109706A1 AR 109706 A1 AR109706 A1 AR 109706A1 AR P170102631 A ARP170102631 A AR P170102631A AR P170102631 A ARP170102631 A AR P170102631A AR 109706 A1 AR109706 A1 AR 109706A1
Authority
AR
Argentina
Prior art keywords
alkyl
phosfatidilinositol
quinasa
dual inhibitors
formula
Prior art date
Application number
ARP170102631A
Other languages
English (en)
Spanish (es)
Inventor
Ulf Brjesson
Peter Bold
Antonios Nikitidis
Christian Tyrchan
Konstantinos Karabelas
Matthew Perry
Jens Petersen
Mickael Mogemark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR109706A1 publication Critical patent/AR109706A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP170102631A 2016-09-22 2017-09-22 INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g AR109706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22

Publications (1)

Publication Number Publication Date
AR109706A1 true AR109706A1 (es) 2019-01-16

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102631A AR109706A1 (es) 2016-09-22 2017-09-22 INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g

Country Status (36)

Country Link
US (2) US10961236B2 (enExample)
EP (1) EP3515910B1 (enExample)
JP (1) JP6765516B2 (enExample)
KR (1) KR102226098B1 (enExample)
CN (1) CN109715623A (enExample)
AR (1) AR109706A1 (enExample)
AU (1) AU2017331940B2 (enExample)
BR (1) BR112019004719A2 (enExample)
CA (1) CA3036304A1 (enExample)
CL (1) CL2019000707A1 (enExample)
CO (1) CO2019003440A2 (enExample)
CR (1) CR20190200A (enExample)
CY (1) CY1123346T1 (enExample)
DK (1) DK3515910T3 (enExample)
DO (1) DOP2019000073A (enExample)
EA (1) EA036176B1 (enExample)
EC (1) ECSP19027780A (enExample)
ES (1) ES2818583T3 (enExample)
HR (1) HRP20201175T1 (enExample)
HU (1) HUE051634T2 (enExample)
IL (1) IL265298B (enExample)
JO (1) JOP20190052A1 (enExample)
LT (1) LT3515910T (enExample)
MA (1) MA46268B1 (enExample)
MX (2) MX381898B (enExample)
PE (1) PE20190909A1 (enExample)
PH (1) PH12019500615A1 (enExample)
PL (1) PL3515910T3 (enExample)
PT (1) PT3515910T (enExample)
RS (1) RS60764B1 (enExample)
SI (1) SI3515910T1 (enExample)
SM (1) SMT202000481T1 (enExample)
SV (1) SV2019005857A (enExample)
TW (1) TW201813967A (enExample)
UA (1) UA123558C2 (enExample)
WO (1) WO2018055040A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
CN115677692A (zh) * 2019-04-10 2023-02-03 南京征祥医药有限公司 磷脂酰肌醇3-激酶抑制剂
JP7665534B2 (ja) 2019-06-04 2025-04-21 アーカス バイオサイエンシーズ インコーポレイテッド 2,3,5-三置換ピラゾロ[1,5-a]ピリミジン化合物
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CA2610884A1 (en) * 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Pi3キナーゼ調節剤および使用方法
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
JP6371838B2 (ja) 2013-07-02 2018-08-08 ライゼン・ファーマシューティカルズ・エスアー Pi3kタンパク質キナーゼ阻害剤、特に、デルタ及び/またはガンマ阻害剤
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
EA031135B1 (ru) 2014-06-27 2018-11-30 Ризен Фармасьютикалз Са Замещенные производные хромена как селективные двойные ингибиторы протеинкиназ pi3 дельта и гамма

Also Published As

Publication number Publication date
MX381898B (es) 2025-03-13
EP3515910B1 (en) 2020-07-15
PT3515910T (pt) 2020-09-16
WO2018055040A1 (en) 2018-03-29
US20200308164A1 (en) 2020-10-01
BR112019004719A2 (pt) 2019-05-28
CA3036304A1 (en) 2018-03-29
ES2818583T3 (es) 2021-04-13
EA036176B1 (ru) 2020-10-09
DOP2019000073A (es) 2019-04-15
JP6765516B2 (ja) 2020-10-07
CY1123346T1 (el) 2022-03-24
KR20190049867A (ko) 2019-05-09
MA46268A (fr) 2019-07-31
PE20190909A1 (es) 2019-06-26
MX2021004748A (es) 2021-06-08
MX2019003194A (es) 2019-06-17
PH12019500615A1 (en) 2019-06-03
JOP20190052A1 (ar) 2019-03-21
US20210246130A1 (en) 2021-08-12
CR20190200A (es) 2019-06-07
LT3515910T (lt) 2020-10-12
EA201990664A1 (ru) 2019-08-30
UA123558C2 (uk) 2021-04-21
ECSP19027780A (es) 2019-04-30
MA46268B1 (fr) 2020-08-31
TW201813967A (zh) 2018-04-16
EP3515910A1 (en) 2019-07-31
HUE051634T2 (hu) 2021-03-01
JP2019529445A (ja) 2019-10-17
KR102226098B1 (ko) 2021-03-09
HRP20201175T1 (hr) 2020-11-13
AU2017331940A1 (en) 2019-05-02
AU2017331940B2 (en) 2020-03-12
SMT202000481T1 (it) 2020-11-10
IL265298A (en) 2019-05-30
US10961236B2 (en) 2021-03-30
CO2019003440A2 (es) 2019-04-12
CL2019000707A1 (es) 2019-05-31
SI3515910T1 (sl) 2020-09-30
DK3515910T3 (da) 2020-08-31
CN109715623A (zh) 2019-05-03
IL265298B (en) 2020-09-30
RS60764B1 (sr) 2020-10-30
SV2019005857A (es) 2019-05-06
PL3515910T3 (pl) 2021-02-22

Similar Documents

Publication Publication Date Title
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR109349A1 (es) Compuestos y usos
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
MX387483B (es) Preparación farmacéutica.
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR095097A1 (es) Compuestos de fenoxietoxi
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR101591A1 (es) Compuestos bicíclicos sustituidos
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure